<h4>Background</h4>We previously reported results from a randomized phase 2 trial evaluating a DNA vaccine (pTVG-HP) versus placebo (GM-CSF vaccine adjuvant alone) in patients with PSA-recurrent, nonmetastatic, non-castrate prostate cancer (NCT01341652). Here, HP is linked to Familial prostate cancer.